- €20.99bn
- €23.48bn
- €22.93bn
- 75
- 57
- 32
- 56
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 15,840 | 11,751 | 15,148 | 25,707 | 22,926 |
Cost of Revenue | |||||
Gross Profit | 3,644 | 2,835 | 3,463 | 3,478 | 3,540 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 13,611 | 10,923 | 13,125 | 23,297 | 21,244 |
Operating Profit | 2,229 | 828 | 2,023 | 2,410 | 1,682 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2,067 | 786 | 1,962 | 2,279 | 1,596 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,789 | 714 | 1,774 | 1,891 | 1,436 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 1,788 | 712 | 1,772 | 1,888 | 1,433 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,788 | 712 | 1,771 | 1,888 | 1,433 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.06 | 1.49 | 1.62 | 2.82 | 2.76 |
Dividends per Share |